S'abonner

Pulse methylprednisolone therapy for severe alopecia areata: An open prospective study of 45 patients - 09/09/11

Doi : 10.1016/S0190-9622(98)70009-X 
A. Friedli, MD, M.P. Labarthe, MD, E. Engelhardt, MD, R. Feldmann, MD, D. Salomon, MD, J-H. Saurat, MD
Department of Dermatology, University Hospital of Geneva. Geneva, Switzerland 

Abstract

Background: Oral corticosteroids may be effective in the treatment of severe alopecia areata (AA), but the side effects of prolonged therapy limit their use. The benefit of a single intravenous pulse of methylprednisolone has not been evaluated in patients with ongoing hair loss of less than 12 months’ duration. Objective: Our purpose was to determine the effectiveness of an intravenous pulse of methylprednisolone at 1, 3, 6, and 12 months in patients with active severe AA of less than 12 months’ duration. Methods: Forty-five patients were included in this open study. All had rapid and extensive hair loss for less than 1 year (first occurrence or relapse), with the bald area exceeding 30% of the scalp. There were 20 multifocal, 10 ophiasic, 9 universalis, and 6 totalis cases. Intravenous methylprednisolone, 250 mg, was administered twice a day on 3 successive days. Follow-up for at least 12 months (up to 29 months) was performed. The percentage of pretreatment bald area covered by hair regrowth at 1, 3, 6, and 12 months was measured. Results: No major side effects were observed. Patients with multifocal AA (n = 20) showed the best response rate, with 9, 12, 13, and 12 showing 100% or 50% to 100% regrowth at 1, 3, 6, and 12 months, respectively. Relapse occurred at 3 months in 1 patient, at 6 months in 2, and at 12 months in 4. A second pulse was tried in 2 patients with relapse with 100% regrowth that was stable at 12 and 28 months. In patients with ophiasic AA (n = 10), no total regrowth was observed; 6 had no response, 4 showed 20% to 70% regrowth at 1 month with relapse at 3 and 6 months. A second series of pulses was given to the 4 initial responders 3 to 13 months after the first series; the response rate to this second treatment was better than the first. In patients with universalis and totalis AA (n = 15), no total regrowth was observed initially; 8 patients had no response, and 3 showed 50% to 90% regrowth at 1 month, with subsequent improvement at 3 and 6 months. In 4 patients who did not show an initial response, a significant (90% to 100%) delayed regrowth was observed between 9 and 16 months after the pulse therapy. Conclusion: A single series of intravenous pulse of methylprednisolone appears to be well tolerated and effective in patients with rapidly progressing extensive multifocal AA, but not those with ophiasic and universalis AA. (J Am Acad Dermatol 1998;39:597-602.)

Le texte complet de cet article est disponible en PDF.

Plan


 Reprint requests: A. Friedli, MD, Department of Dermatology, Hôpital Cantonal Universitaire, 1211 Geneve 14, Switzerland.
 0190-9622/98/$5.00 + 0  16/1/92422


© 1998  American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 39 - N° 4

P. 597-602 - octobre 1998 Retour au numéro
Article précédent Article précédent
  • Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis
  • Mark G. Lebwohl, Debra L. Breneman, Bernard S. Goffe, Jay R. Grossman, Mark R. Ling, James Milbauer, Stephanie H. Pincus, R.Gary Sibbald, Leonard J. Swinyer, Gerald D. Weinstein, Deborah A. Lew-Kaya, John C. Lue, John R. Gibson, John Sefton
| Article suivant Article suivant
  • Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma
  • Frank L. Glass, John A. Cottam, Douglas S. Reintgen, Neil A. Fenske

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.